CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.23
+0.02 (+6.98%)
At close: 2:26PM EST
Stock chart is not supported by your current browser
Previous Close0.22
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume6,815
Market Cap10.13M
Beta-2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cell MedX Corp. :CMXC-US: Earnings Analysis: 2017 By the Numbers : October 12, 2017
    Capital Cube2 months ago

    Cell MedX Corp. :CMXC-US: Earnings Analysis: 2017 By the Numbers : October 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Cell MedX Corp. reports financial results for the year ended May 31, 2017. Highlights Gross margins narrowed from -34.09% to -1,943.36% compared to the same period last year, operating (EBITDA) margins now -17,669.44% from -5,699.73%. Change in operating cash flow of -78.87% compared to same period last year is about the ... Read more (Read more...)

  • Newsfile4 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - August 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with the corporate update on its current operations. Private PlacementThe Company's board of directors has approved a private placement offering of up to 8,000,000 units of the ...

  • Newsfile5 months ago

    Cell MedX Corp. Provides Update on its Clinical Observational Trial

    Carson City, Nevada--(Newsfile Corp. - July 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that all 30 subjects taking part in the Company's ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") have ...

  • Newsfile5 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - July 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that its currently ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") is nearing its completion. To date, 29 ...

  • Cell MedX Corp. :CMXC-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017
    Capital Cube7 months ago

    Cell MedX Corp. :CMXC-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017

    Categories: Yahoo FinanceGet free summary analysis Cell MedX Corp. reports financial results for the quarter ended February 28, 2017. We analyze the earnings along side the following peers of Cell MedX Corp. – Town Sports International Holdings, Inc. (CLUB-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of ... Read more (Read more...)

  • Cell MedX Corp. :CMXC-US: Earnings Analysis: Q2, 2017 By the Numbers : January 23, 2017
    Capital Cube11 months ago

    Cell MedX Corp. :CMXC-US: Earnings Analysis: Q2, 2017 By the Numbers : January 23, 2017

    Categories: Yahoo Finance Get free summary analysis Cell MedX Corp. reports financial results for the quarter ended November 30, 2016. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -1.06 million. Gross margins widened from -7,751.47% to -5,462.50% compared to the same period last year, operating (EBITDA) margins now -66,419.35% from -12,663.31%. Change in operating ... Read more (Read more...)